Circulation Heart Failure· 2026Q1
Get With The Guidelines–Heart Failure Hastane Katılımının Kılavuz Odaklı Tıbbi Tedavi ve Sonuçlarla İlişkisi
Get With The Guidelines–Heart Failure Hospital Participation and Its Association With Guideline-Directed Medical Therapy and Outcomes
- 1atıf
- Q1SCImago
- 2026yıl
Kısa özet
Get With The Guidelines–Heart Failure (GWTG-HF) programına katılan hastaneler, katılmayanlara kıyasla %0.15 daha yüksek 90 günlük GDMT puanı ve 30 gün, 90 gün ve 1 yıl içinde önemli ölçüde azalmış tüm nedenlere bağlı ölüm oranları gösterdi.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- GWTG-HF'ye katılan hastaneler, katılmayanlara göre 90 günlük GDMT puanında 0.15 puan daha yüksek skor elde etti.
- GWTG-HF katılımı, beta bloker, RASI ve MRA kullanımında artışla ilişkilendirildi.
- GWTG-HF'ye katılan hastanelerde 30 günlük (OR 0.95), 90 günlük (OR 0.97) ve 1 yıllık (0.97) tüm nedenlere bağlı ölüm oranları anlamlı derecede düşüktü.
- Katılan ve katılmayan hastaneler arasında KY yeniden yatış oranlarında anlamlı bir fark gözlenmedi.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
Abstract Purpose Despite strong evidence, real-world adoption of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal. The Get With The Guidelines–Heart Failure (GWTG-HF) program was designed to close gaps in care. We evaluated whether hospital participation in GWTG-HF is associated with greater GDMT intensity and improved outcomes. Methods We conducted a retrospective analysis (2013-2021) of Medicare beneficiaries with Part A and Part D hospitalized with HFrEF. Using a multiple baseline time series design, we compared changes in GDMT prescribing and outcomes at hospitals before and after GWTG-HF enrollment with hospitals that never participated. The primary outcome was a 90-day post-discharge prescription-fill GDMT score summarizing use and dose of beta blockers, renin-angiotensin system inhibitors (RASI; ACE inhibitor/ARB/ARNI), and mineralocorticoid receptor antagonists (MRA). Secondary outcomes included class-specific medication fills, achievement of ≥50% target doses, and 30-day, 90-day, and 1-year all-cause and HF readmission and mortality. We adjusted for baseline hospital performance, patient characteristics, and temporal trends. Results Among 1,274,863 Medicare beneficiaries hospitalized for HFrEF, 53.5% were treated at hospitals that never participated in GWTG-HF and 9.6% at hospitals that joined GWTG-HF before hospitalization. Unadjusted median GDMT scores increased from 3.0 in both groups to 4.0 in non-participating hospitals and 4.5 in GWTG-HF hospitals at 90 days (p<0.001). Hospital enrollment was associated with a higher 90-day GDMT score (+0.15 points; 95% CI 0.12-0.18; p<0.001), and greater use of beta blockers, RASI, and MRA, but not ARNI. HF readmission did not differ significantly; however, GWTG-HF participation was associated with lower all-cause mortality at 30 days (OR 0.95; 95% CI:0.92-0.98), 90 days (OR: 0.97; 95% CI: 0.95-0.99), and 1 year (0.97; 95% CI: 0.95-.0.99; all p<0.05). Conclusion Hospital participation in GWTG-HF was associated with higher GDMT intensity and lower mortality, supporting structured quality programs to improve HFrEF care.
Yazarların özeti; kaynağından alınmıştır. Circulation Heart Failure, 2026 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Kardiyoloji ve Kardiyovasküler Tıp
Cardiology and Cardiovascular MedicineMedicine